Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

Daiichi Sankyo clinical trials

The registry lists 498 studies whose lead sponsor is Daiichi Sankyo or one of 14 companies grouped under it. 39 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Keep track of what changes. Save the Daiichi Sankyo studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Status

Completed: 370
Terminated: 42
Recruiting: 34
Active, not recruiting: 30
Withdrawn: 12
Not yet recruiting: 4

Phase

Phase 1: 158
Phase 2: 131
Phase 3: 130
Phase 4: 37
Early Phase 1: 4

Where

United States: 302
Japan: 123
Spain: 84
Germany: 81
France: 79
United Kingdom: 76

Focus areas

Conditions Daiichi Sankyo leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Hypertension43 Carcinoma, Non-Small-Cell Lung35 Diabetes Mellitus, Type 230 Anemia26 Neoplasms25 Atrial Fibrillation22 Breast Neoplasms22 Essential Hypertension22 Leukemia21 Anemia, Iron-Deficiency20 Leukemia, Myeloid, Acute20 Venous Thromboembolism14 Hypercholesterolemia13 Kidney Diseases13 Colorectal Neoplasms12 Neoplasm Metastasis11

Studies

Recruiting first, then most recently updated. Showing 50 of 498. Browse all 498 →